Mizuho analyst Gregg Moskowitz recently held a conference call with a Senior Director at a large consulting firm specializing in data cloud and database technologies.
Health Catalyst, Inc. (NASDAQ: HCAT) fell 33.5% to $12.14 after the company issued weak sales forecast and announced a $40 million share repurchase program. JP Morgan and Stifel also downgraded the stock.